Mr. Poolside
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It’s actually a few blocks up
But cedars Sinai has lots of buildings not just 1
This one needs to settle.
Double digit next week
They have gotten FDA approval, and FDA just asked for a second trial just like they did with remdesivir.
If this is 20/20 like the 6/6 - this will go to major media and $100 per share
A big pharma can just partner or buy this out
Shorts brought this down $1.00
We need this covered
Lol that’s a slow and steady short
I got a bunch at 1.46
$$$
Lol
Damn
Especially considering the platform is proven to save lives
This company already has fully approvable primary and secondary endpoints on the 6 Month data set
The 12 month data will introduce in depth analysis, which is key for accelerated approval
Great chances
FDA already approved CAP1002 treatment for a different indication
If numbers add up, and they do based on 6 month data, I see accelerated approval
In this case the risk is not worth it period
I can see this gap to $20-$40 in many different ways.
BARDA can give us $100 million for covid vaccine
And/or
Big pharma partnership to help develop it
And/or
Accelerated DMD treatment approval
And/or
Positive FDA update on 20 patients
And/or
Hedge funds buying in
And/or
Forward split
Yes. We’re talking catastrophic losses
Lol shorts don’t have to cover they will be forced to cover.
It costs money to borrow shares on top of the risk of going short
I know one short who got wiped twice today
I would
It’s been so far with their other trials too.
Do some DD
The trial is ongoing and direct data
FDA can approve anytime, and since it’s approved, they can now dose more patients at a time
I don’t imagine more than a week or two at most
That’s what this is
Compassionate use extended trial
They will test up to 20 more people
Imagine 26/26
This will go on a ripping spree
FDA might grant P1 for covid 19 vaccine in conjunction w a barda grant and or a partnership
That’s what that 20 people trial is
In my view
If they get accelerated approval this will hit $25 - $30
Just needs some hard press coverage
And this will gap to $50
It is the only drug with 100% success.
You have to realize this is untapped market, not even big pharma treat critical DNR patients - and they walk home next few days
This Does
6.53
Great call
Short bus covering
This is bottom
I am thinking it will rise continuously after today’s consolidation
Yes that’s right
Another big news takes this to $20
There is ton of back and forth
This is virtually all traders
Relax fellas this is a normal trader sell off and funny money shorting a little
Will close 8s by Friday
Yea. But it will settle
Day trading is good
This will likely settle on 7s today
When this settles, it’s going to go up
News is just accelerating that prerogative
And there’s so much of It coming
Technically it was most likely less
There was lots of back and forth
I know someone who sold and bought 16x yesterday
It’s the same thing.
That’s their marketing name
Well obviously
Hydroxychloroquine doesn’t even target critical patients
This specifically and by design does
The shorts will lose their house when this gaps $20+
There’s absolutely no hope for 86% of DMD patients because exondys51 (only fda approved drug on the market) treats only 14 % of DMD patients.
This is where we step in.
CAP1002 is designed to target non ambulant DMD patients, who lost motility of upper limb - 10,000 patients in USA with an estimated treatment costs $200k per year per patient (about 30-50% below market all the other gene and cells therapies)
Check the 6 month data - very compelling
The big win will be the DMD drug
Minimum $20 within few weeks
Nah
Lol
Good job man